Ribavirin Patent Expiration
Ribavirin is Used for treating infections and infestations by modulating cytokine responses in lymphocytes. It was first introduced by Bausch Health Us Llc
Ribavirin Patents
Given below is the list of patents protecting Ribavirin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rebetol |
US6790837 (Pediatric) | Ribavirin syrup formulations |
Oct 05, 2023
(Expired) | Schering |
| Rebetol | US6790837 | Ribavirin syrup formulations |
Apr 05, 2023
(Expired) | Schering |
| Rebetol |
US6172046 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar 21, 2018
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6172046 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar 21, 2018
(Expired) | Schering |
| Rebetol |
US6472373 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar 21, 2018
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6472373 (Pediatric) | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar 21, 2018
(Expired) | Schering |
| Virazole | US6150337 | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
Nov 21, 2017
(Expired) | Bausch |
| Rebetol | US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep 21, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol | US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep 21, 2017
(Expired) | Schering |
| Rebetol | US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep 21, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol | US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep 21, 2017
(Expired) | Schering |
| Rebetol |
US6177074 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6177074 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol |
US6461605 (Pediatric) | Continuous low-dose cytokine infusion therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6461605 (Pediatric) | Continuous low-dose cytokine infusion therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol |
US6524570 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Merck Sharp Dohme |
| Rebetol |
US6524570 (Pediatric) | Polyethylene glycol modified interferon therapy |
May 01, 2017
(Expired) | Schering |
| Rebetol | US6177074 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6177074 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Schering |
| Rebetol | US6461605 | Continuous low-dose cytokine infusion therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6461605 | Continuous low-dose cytokine infusion therapy |
Nov 01, 2016
(Expired) | Schering |
| Rebetol | US6524570 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Merck Sharp Dohme |
| Rebetol | US6524570 | Polyethylene glycol modified interferon therapy |
Nov 01, 2016
(Expired) | Schering |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ribavirin's patents.
Latest Legal Activities on Ribavirin's Patents
Given below is the list recent legal activities going on the following patents of Ribavirin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 26 Aug, 2011 | US6790837 |
| Post Issue Communication - Certificate of Correction | 05 Mar, 2007 | US6790837 |
| Post Issue Communication - Certificate of Correction | 26 Oct, 2005 | US6461605 |
| Recordation of Patent Grant Mailed Critical | 14 Sep, 2004 | US6790837 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Sep, 2004 | US6790837 |
| Issue Notification Mailed Critical | 26 Aug, 2004 | US6790837 |
| Receipt into Pubs | 20 Aug, 2004 | US6790837 |
| Dispatch to FDC | 19 Aug, 2004 | US6790837 |
| Application Is Considered Ready for Issue Critical | 19 Aug, 2004 | US6790837 |
| Receipt into Pubs | 18 Aug, 2004 | US6790837 |
Ribavirin's Family Patents
Explore Our Curated Drug Screens
Ribavirin Generic API Manufacturers
Several generic applications have been filed for Ribavirin. The first generic version for Ribavirin was by Chartwell Rx Sciences Llc and was approved on Apr 6, 2004. And the latest generic version is by Navinta Llc and was approved on Oct 6, 2016.
Given below is the list of companies who have filed for Ribavirin generic, along with the locations of their manufacturing plants worldwide.
1. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Ribavirin. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG
(reference standard) | capsule | Prescription | ORAL | AB | Sep 17, 2009 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
2. BEXIMCO PHARMS USA
Beximco Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Ribavirin. Given below are the details of the strengths of this generic introduced by Beximco Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Discontinued | ORAL | N/A | Aug 12, 2014 |
| 400MG | tablet | Discontinued | ORAL | N/A | Aug 12, 2014 |
| 500MG | tablet | Discontinued | ORAL | N/A | Aug 12, 2014 |
| 600MG | tablet | Discontinued | ORAL | N/A | Aug 12, 2014 |
3. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 3 different strengths of generic version for Ribavirin. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2005 |
| 600MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2005 |
| 400MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2005 |
4. HERITAGE PHARMA AVET
Heritage Pharma Labs Inc Dba Avet Pharmaceuticals Labs Inc has filed for 1 generic for Ribavirin. Given below are the details of the strengths of this generic introduced by Heritage Pharma Avet.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Discontinued | ORAL | N/A | Dec 5, 2005 |
5. NAVINTA LLC
Navinta Llc has filed for 1 generic for Ribavirin. Given below are the details of the strengths of this generic introduced by Navinta Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6GM/VIAL | for solution | Prescription | INHALATION | AN | Oct 6, 2016 |
6. SANDOZ
Sandoz Inc has filed for 1 generic for Ribavirin. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Oct 3, 2006 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
7. TEVA
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Ribavirin. Given below are the details of the strengths of this generic introduced by Teva.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | capsule | Discontinued | ORAL | N/A | Oct 4, 2004 |
Manufacturing Plant Locations New
Teva's manufacturing plants are situated in 6 countries - United States, India, Canada, Czech Republic, Ireland, Israel. Given below are the details of these plant locations as well as the firm names of Teva as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| India |
| |||||||||
| Canada |
| |||||||||
| Czech Republic |
| |||||||||
| Ireland |
| |||||||||
| Israel |
| |||||||||
8. ZYDUS PHARMS USA
Zydus Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Ribavirin. Given below are the details of the strengths of this generic introduced by Zydus Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Dec 5, 2005 |
| 600MG | tablet | Discontinued | ORAL | N/A | Mar 16, 2007 |
| 400MG | tablet | Discontinued | ORAL | N/A | Mar 16, 2007 |
| 500MG | tablet | Discontinued | ORAL | N/A | Apr 18, 2008 |